Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Selective Inhibition of Acetylcholine-Evoked Responses of α7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists

Gretchen Y. López-Hernández, Jeffrey S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin and Roger L. Papke
Molecular Pharmacology September 2009, 76 (3) 652-666; DOI: https://doi.org/10.1124/mol.109.056176
Gretchen Y. López-Hernández
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Thinschmidt
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangrong Zheng
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhenfa Zhang
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter A. Crooks
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda P. Dwoskin
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger L. Papke
Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, Florida (G.Y.L.-H., J.S.T., R.L.P.); and Department of Pharmaceutical Science, University of Kentucky, College of Pharmacy, Lexington, Kentucky (G.Z., Z.Z., P.A.C., L.P.D.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

A family of 20 tris-azaaromatic quaternary ammonium (AQA) compounds were tested for their inhibition of α7 nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus laevis oocytes. The potency of inhibitory activity was related to the hydrophobic character of the tris head groups. Two tris-AQA compounds were studied in detail: the highly effective inhibitor 1,3,5-tri-[5-(1-quinolinum)-pent-1-yn-1-yl]-benzene tribromide (tPyQB) and the less potent antagonist 1,3,5,-tri-{5-[1-(2-picolinium)]-pent-1-yn-1-yl}benzene tribromide (tPy2PiB). In addition, we evaluated 1,2,4,5-tetra-{5-[1-(3-benzyl)pyridinium]pent-1-yl}benzene tetrabromide (tkP3BzPB), a tetrakis-AQA with very hydrophobic headgroups. We compared the activity of the AQA compounds to the frequently used α7-antagonist methyllycaconitine (MLA). Both tPyQB and tkP3BzPB were selective antagonists of α7. However, although inhibition by tPyQB was reversible within 5 min, the recovery time constant for tkP3BzPB inhibition was 26.6 ± 0.8 min, so that the equilibrium inhibition in the prolonged presence of nanomolar concentrations of tkP3BzPB was nearly 100%. The potency, selectivity, and slow reversibility of tkP3BzPB were comparable with or greater than that of MLA. The inhibitory actions of tPyQB, tPy2PiB, and tkP3BzPB were evaluated on the acetylcholine (ACh)-evoked responses of native nAChRs in rat brain slices. The α7-mediated responses of hippocampal interneurons were effectively reduced by 1 μM tPyQB and tkP3BzPB but not tPy2PiB. In rat medial septum, tkP3BzPB produced a greater inhibition of ACh-evoked responses of cells with fast inward currents (type I) than of cells with predominantly slow kinetics (type II), suggesting that tkP3BzPB can block α7 yet preserve the responsiveness of non-α7 receptors. These agents might be helpful in elucidating complex receptor responses in brain regions with mixed populations of nAChRs.

Footnotes

    • Received March 12, 2009.
    • Accepted June 25, 2009.
  • This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grant U19-DA017548], the National Institutes of Health National Institute of General Medical Sciences[Grant R01-GM057481], and the National Institutes of Health National Institute on Aging [Grants P01-AG010485, T32-AG000196].

  • A portion of this work was previously presented in abstract form: López GY, Thinschmidt JS, Zheng G, Zhang Z, Crooks PA, Dwoskin LP, and Papke RL. Differential inhibition of ACh-evoked responses of neuronal nicotinic receptors in rat brain slices by selective nAChR antagonists. Society for Neuroscience Satellite Symposium on “Nicotinic Acetylcholine Receptors as Therapeutic Targets—Emerging Frontiers in Basic Research and Clinical Science”; San Diego, CA; 2007 Oct 31-Nov 2; Poster 1.31.

  • The University of Kentucky holds patents on the tris- and tetrakis-azaaromatic quaternary ammonium compounds described herein. A potential royalty stream to L.P.D. and P.A.C. may occur consistent with University of Kentucky policy.

  • ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; CNS, central nervous system; MS/DB, medial septum/diagonal band; MLA, methyllycaconitine; tPy2PiB, 1,3,5,-tri-{5-[1-(2-picolinium)]-pent-1-yn-1-yl}benzene tribromide; tPyQB, 1,3,5-tri-[5-(1-quinolinum)-pent-1-yn-1-yl]-benzene tribromide; tkP3BzPB, 1,2,4,5-tetra-{5-[1-(3-benzyl)pyridinium]pent-1-yl}benzene tetrabromide; AQA, azaaromatic quaternary ammonium; PNU-120596, 1-(5-chloro-2,4-dimethoxy-phenyl)-3-(5-methyl-isoxanol-3-yl)-urea; ACh, acetylcholine; DHβE, dihydro-β-erythroidine; 5-HT, 5-hydroxytryptamine; TMPH, 2,2,6,6-tetramethylpiperidin-4-yl heptanoate; GTS-21, 3-2,4,dimethoxy-benzylidene anabaseine; VTA, ventral tegmental area.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 76 (3)
Molecular Pharmacology
Vol. 76, Issue 3
1 Sep 2009
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selective Inhibition of Acetylcholine-Evoked Responses of α7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Selective Inhibition of Acetylcholine-Evoked Responses of α7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists

Gretchen Y. López-Hernández, Jeffrey S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin and Roger L. Papke
Molecular Pharmacology September 1, 2009, 76 (3) 652-666; DOI: https://doi.org/10.1124/mol.109.056176

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Selective Inhibition of Acetylcholine-Evoked Responses of α7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists

Gretchen Y. López-Hernández, Jeffrey S. Thinschmidt, Guangrong Zheng, Zhenfa Zhang, Peter A. Crooks, Linda P. Dwoskin and Roger L. Papke
Molecular Pharmacology September 1, 2009, 76 (3) 652-666; DOI: https://doi.org/10.1124/mol.109.056176
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Michaelis Menten quantification of GPCR-G protein signalling
  • Human mAb 3F1 targeting the fuctional epitopes of Siglec-15
  • The regulation and mechanisms of ImKTX58 on KV1.3 channel
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics